Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients

Journal of Neuro-Ophthalmology

Volumn 26, Issue 1, 2006, Pages 25-29

  Koc, Feray ^a,b   Kansu, Tulay ^a   Kavuncu, Sevim ^a   Firat, Esin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; AUTONOMIC DENERVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE DURATION; EYELID RETRACTION; FEMALE; HUMAN; MALE; MIOSIS; MYDRIASIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PUPIL; PUPILLARY SYMPATHETIC DENERVATION; ADRENERGIC SYSTEM; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG INSTILLATION; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; CLONIDINE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; INSTILLATION, DRUG; MALE; MIDDLE AGED; MYDRIASIS; PUPIL; SEVERITY OF ILLNESS INDEX; SYMPATHETIC NERVOUS SYSTEM;

EID: 33646846122     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wno.0000204648.79744.71     Document Type: Article

References (28)

1. McNally PG, Lawrence IG, Panerai RB, et al. Sudden death in type-1 diabetes. Diabetes Obes Metab 1999;1:151-8.
2. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. J Med 1980;49:95-108.
3. Ewing DJ, Clarke BF. Autonomic neuropathy: Its diagnosis and prognosis. Clin Endocrinol Metab 1986;15:855-88.
4. Hreidarsson AB. The pupil of the eye in diabetes mellitus, an indicator of autonomic nervous dysfunction. Dan Med Bull 1992;39:400-8.
5. Terkildsen AB, Christensen NJ. Reversible nervous abnormalities in juvenile diabetics with recently diagnosed diabetes. Diabetologia 1971;7:113-7.
6. Santiago JV. Lessons from the Diabetes Control and Complications Trial. Diabetes 1993;42:1549-54.
7. Sharma S, Hoskin-Mott A, Benstead T, et al. Correlation of the pilopupil ratio average, a new test for autonomic denervation, to the severity of diabetic retinopathy. Can J Ophthalmol 1997;32:170-4.
8. Cahill M, Eustace P, De Jesus V. Pupillary autonomic denervation with increasing duration of diabetes mellitus. Br J Ophthalmol 2001;85:1225-30.
9. Clark CV. Ocular autonomic nerve function in proliferative diabetic retinopathy. Eye 1988;2:96-101.
10. Smith SA, Smith SE. Evidence for a neuropathic aetiology in the small pupil of diabetes mellitus. Br J Ophthalmol 1983;67:89-93.
11. Pittasch D, Lobmann R, Behrens-Baumann W, et al. Pupil signs of sympathetic autonomic neuropathy in patients with type 1 diabetes. Diabetes Care 2002;25:1545-50.
12. Morales J, Brown SM, Abdul-Rahim AS, et al. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol 2000;118:951-4.
13. Brown SM, Aouchiche R, Freedman KA. The utility of 0.5% apraclonidine in the diagnosis of Horner syndrome. Arch Ophthalmol 2003;121:1201-3.
14. Koc F, Kavuncu S, Kansu T, et al. The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. Br J Ophthalmol 2005;89:1442-4.
15. Crosson CE, Heath AR, DeVries GW, et al. Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Curr Eye Res 1992;11:963-70.
16. Potter DE, Crosson CE Heath AR, et al. Review: alpha 2 DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol 1990;6:251-7.
17. Langham ME, Weinstein GW. Horner's syndrome: ocular supersensitivity to adrenergic amines. Arch Ophthalmol 1967;78:462-9.
18. Yoon KC, Im SK, Seo MS. Changes of tear film and ocular surface in diabetes mellitus. Korean J Ophthalmol 2004;18:168-74.
19. Saito J, Enoki M, Hara M, Morishige N, Chikama T, Nishida T. Correlation of corneal sensation, but not of basal or reflex tear secretion with the stage of diabetic retinopathy. Cornea 2003;22:15-8.
20. Inoue K, Kato S, Ohara C, et al. Ocular and systemic factors relevant to diabetic keratoepitheliopathy. Cornea 2001;20:798-801.
21. Gekka M, Miyata K, Nagai Y, et al. Corneal epithelial barrier function in diabetic patients. Cornea 2004;23:35-7.
22. Abrams DA, Robin AL, Pollack IP, et al. The safety and efficacy of topical 1% alo 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987;105:1205-7.
23. Jampel HD, Robin AL, Quigley HA, et al. Apraclonidine. a one-week dose-response study. Arch Ophthalmol 1988;106:1069-72.
24. Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988;106:912-5.
25. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996;114:938-42.
26. Korczyn AD, Laor N, Nemet P. Sympathetic pupillary tone in old age. Arch Ophthalmol 1976;94:1905-6.
27. Clark CV. Autonomic neuropathy in proliferative diabetic retinopathy. Eye 1987;1:496-9.
28. Smith SE, Smith SA, Brown PM. Cardiac autonomic dysfunction in patients with diabetic retinopathy. Diabetologia 1981;21:525-8.